NASDAQ$RIGL
Rigel Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results, including record revenues from TAVALISSE and REZLIDHIA, and successful transfer of GAVRETO to the commercial portfolio.
Rigel Pharmaceuticals reported total revenues of $36.8 million for the second quarter of 2024, driven by record sales of TAVALISSE and REZLIDHIA, as well as the addition of GAVRETO to their commercial portfolio. The company reported a net loss of $1.0 million, approaching net income break even.
- Total revenues were $36.8 million, driven by TAVALISSE, REZLIDHIA, GAVRETO net product sales, and contract revenue from collaborations.
- TAVALISSE net product sales grew 24% compared to the same period in 2023.
- REZLIDHIA net product sales grew 102% compared to the same period in 2023.
- GAVRETO became commercially available from Rigel on June 27, 2024.
Headline financials
Revenue & EPS history
Rigel · Revenue · Quarterly
$36.8M
Revenue by segment
Rigel · $2M total across 1 segment · Q2 2023
- Collaboration Revenue$2M-82.3%100.0%
Forward guidance
The company looks to maintain their financial discipline as they expand their commercial reach and advance their development programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.2%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+2.8%
Avg return
30 days after
38%
25 / 65 earnings
Positive
+46.4%
Q3 2024
Best reaction
-18.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.8% | -11.8% | +2.3% | |
| Q4 2025 | -10.2% | -15.0% | -16.6% | |
| Q3 2025 | -2.6% | +10.6% | +35.4% | |
| Q1 2025 | +0.9% | +1.9% | +17.7% | |
| Q4 2024 | -8.1% | -11.5% | -21.9% | |
| Q3 2024 | +46.4% | +80.5% | +68.8% | |
| Q2 2024 | +12.2% | +16.0% | +52.4% | |
| Q1 2024 | -18.7% | -19.7% | -21.3% | |
| Q4 2023 | +6.1% | +6.8% | -12.2% | |
| Q3 2023 | +5.8% | -2.4% | +35.7% | |
| Q2 2023 | -6.5% | -11.6% | -17.4% | |
| Q1 2023 | -3.4% | -0.8% | +17.6% | |
| Q4 2022 | +17.8% | +4.6% | -17.8% | |
| Q3 2022 | +5.3% | +4.3% | +18.6% | |
| Q2 2022 | +16.5% | +25.6% | +27.3% | |
| Q1 2022 | +7.3% | -9.8% | -32.5% | |
| Q4 2021 | +21.1% | +21.1% | +19.1% | |
| Q3 2021 | -1.7% | -8.8% | -26.3% | |
| Q2 2021 | -7.2% | -5.2% | +3.2% | |
| Q1 2021 | -5.2% | -7.8% | +15.7% | |
| Q4 2020 | -14.3% | -14.1% | -23.3% | |
| Q3 2020 | -3.0% | +1.5% | +14.1% | |
| Q2 2020 | +3.7% | +6.2% | -4.5% | |
| Q1 2020 | -2.2% | -2.7% | +2.2% | |
| Q4 2019 | -2.3% | +0.5% | -27.6% | |
| Q3 2019 | -1.9% | +4.7% | -5.1% | |
| Q2 2019 | +8.1% | +1.9% | -15.7% | |
| Q1 2019 | -5.5% | -6.7% | -14.7% | |
| Q4 2018 | -0.9% | -1.8% | +13.7% | |
| Q3 2018 | +7.2% | -2.7% | -3.8% | |
| Q2 2018 | +10.2% | +1.1% | +16.8% | |
| Q1 2018 | +5.3% | +7.2% | -10.0% | |
| Q4 2017 | +13.5% | +14.5% | -18.1% | |
| Q3 2017 | +1.1% | +1.6% | +2.4% | |
| Q2 2017 | -1.3% | +1.7% | +7.6% | |
| Q1 2017 | -9.9% | -9.2% | -19.1% | |
| Q4 2016 | +2.6% | +0.8% | +14.3% | |
| Q3 2016 | -3.1% | +1.5% | -3.5% | |
| Q2 2016 | +14.3% | +22.7% | +37.5% | |
| Q1 2016 | -10.9% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +8.9% | — | — | |
| Q2 2015 | +4.6% | — | — | |
| Q1 2015 | -10.5% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | -10.6% | — | — | |
| Q4 2013 | +17.5% | — | — | |
| Q3 2013 | -9.3% | — | — | |
| Q2 2013 | +2.8% | — | — | |
| Q1 2013 | -0.6% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q4 2009 | -9.0% | — | — | |
| Q4 2011 | -9.0% | — | — | |
| Q3 2010 | -5.9% | — | — | |
| Q3 2011 | -5.9% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | -11.5% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro